Lurbinectedin, a medication used in cancer treatment, poses potential risks to pregnant women. The drug is classified as Pregnancy Category D by the FDA, indicating evidence of fetal risk based on human data. Lurbinectedin can cause fetal harm when administered to pregnant women due to its mechanism of action and potential side effects. It is advised to avoid pregnancy during treatment with lurbinectedin and for at least 6 months after the last dose. Pregnant women should be informed of the potential risks to the fetus if exposed to lurbinectedin. It is crucial for healthcare providers to discuss the risks and benefits of treatment with lurbinectedin with female patients of reproductive potential and to provide appropriate contraceptive counseling to prevent pregnancy-related complications [2].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf